ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California
CIRM has developed a unique funding opportunity for non-profit academic GMP manufacturing facilities to enhance operations and to establish productive partnerships with industry and non-profit stakeholders to further establish
"CIRM's California Manufacturing Network initiative recognizes the integral role that
"It's gratifying to know that the G-Rex manufacturing platform is being widely adopted by
The following G-Rex Grants were awarded to these CIRM INFR5 Recipients:
-
Dr. Dan Kaufman, Professor of Medicine and Director of the Cell Therapy Program at the
University of California, San Diego (UCSD), was awarded a$125,000 G-Rex Grant to support the development of a novel G-Rex® based production system to manufacture novel virus-like particles for in vivo immune cell engineering. -
Dr. Taby Ahsan, Vice President of Cell & Gene Therapy at
City of Hope , was awarded a$300,000 G-Rex Grant to support the continuation of process development efforts on a G-Rex based CAR-T cell therapy production method. The first clinically available CAR-T cell therapy produced in G-Rex atCity of Hope will come from the lab of Dr.Xiuli Wang , also a G-Rex Grant Recipient and professor in theDepartment of Hematology & Hematopoietic Cell Transplantation atCity of Hope . -
Dr. Steve Feldman, Site Head and Scientific Director of Stanford Medicine's
Laboratory for Cell & Gene Medicine (LCGM), was awarded a$300,000 G-Rex Grant to develop a G-Rex process for manufacturing CAR-T cell therapies. The first CAR-T cell therapy produced in G-Rex at Stanford Medicine's LCGM recently entered the clinic for GPC2+ pediatric neuroblastoma and medulloblastoma. -
Dr. Mohamed Abou-el-Enein, Executive Director of the
University of Southern California (USC) /Children's Hospital of Los Angeles (CHLA) Cell Therapy Program and Founding Director of the cGMP Facility, was awarded a$300,000 G-Rex Grant to further support the development of a novel non-viral manufacturing platform for CAR-T cell therapies. -
Mr.
Brian Fury , Director of theUniversity of California, Davis (UCD) GMP facility, was awarded a$300,000 G-Rex Grant for process development and platform improvements on a G-Rex centric approach to CAR-T cell manufacturing to support both internal investigators and external industry-sponsors. -
Dr.
Brian Shy , Director of the Human Islet and Cellular Transplantation GMP Facility (HICTF) and Dr.Ke Li , Head ofProcess Development , Investigational Cellular Therapy at theUniversity of California, San Francisco (UCSF) received a$200,000 G-Rex Grant to make improvements to their existing G-Rex based open-source, fully-non viral CAR-T cell therapy engineering platform. UCSF recently celebrated theFDA's clearance of the investigational new drug (IND) application for their first non-viral anti-BCMA CAR-T cell therapy. The team is working on the second non-viral (anti CD70) CAR-T cell therapy that will be tech transferred from the lab of Dr.Arun Wiita , also a G-Rex Grant Recipient. -
Dr.
Dawn Ward , Medical Director of the Human Gene & Cell Therapy Facility at theUniversity of California, Los Angeles (UCLA), received a$150,000 G-Rex Grant to establish multiple G-Rex based workflows for producing different cell therapy modalities at the new GMP facility. The first cell therapy produced in G-Rex is expected to be a novel invariant natural killer T (iNKT) cell therapy developed byUCLA's Dr.Lili Yang , also a G-Rex Grant Recipient. -
Dr. Dhruv Sareen, Executive Director of the Cedars Sinai Biomanufacturing Center (CBC), received a
$300,000 G-Rex Grant to support the preclinical development and IND-enabling studies for a novel CAR-T cell therapy targeting pancreatic adenocarcinoma. This therapy was developed in the lab of Dr.Joshua Sasine , also a G-Rex Grant Recipient, and will be the first CAR-T cell therapy developed and manufactured at Cedars Sinai.
ScaleReady's G-Rex Grant Program is a
Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with
For more information about LEAN Cell & Gene™, please use this link to register for the free event series.
For more information about the G-Rex® Grant Program, please contact i nfo@scaleready.com.
Disclaimer: Reference to CIRM or its awardees in this announcement does not constitute or imply endorsement of ScaleReady or its products by CIRM.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
About
Contact:
david.clair@bio-techne.com
612-656-4416
About
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-awards-g-rex-grants-to-support-cell-and-gene-therapy-manufacturing-in-california-302548014.html
SOURCE
